Endocrine Cancer News
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.
The approval was based on data from the phase 1/2 ARROW trial which evaluated the efficacy and safety of Gavreto in patients with RET-mutant MTC.
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
Treatment of RET-altered thyroid cancer with selpercatinib, a RET inhibitor, resulted in durable efficacy with a tolerable safety profile in a phase 1/2 trial.
The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources.
It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.
Black patients were half as likely to receive remdesivir as White patients, according to researchers from the CCC19.
New research presented at ASCO 2020 sheds light on conflicts of interest among NCCN panelists and links industry dollars to measures of academic success among junior faculty.
Two recent papers are encouraging cancer center executives to rethink how they position their services to potential patients.
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Specifically, unacceptable levels of this potentially carcinogenic impurity have been identified in products manufactured by 5 different firms.
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
The FDA has granted accelerated approval to Retevmo™ (selpercatinib; Lilly).
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
Higher incidence of thyroid cancer in World Trade Center-exposed emergency workers is likely due to greater detection of asymptomatic thyroid cancer.
The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing.
Although papillary thyroid carcinoma subtypes are often lumped together, mortality risk varied greatly across subtypes.
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
CRISPR-modified T cells were used in 3 patients with advanced cancer for the first time, showing modest results on tumor growth.
New research shows that B cells — and not just T cells — influence whether patients respond to immunotherapy in melanoma, sarcoma, and kidney cancers.
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.
ASCO outlined advances in oncology that were the most clinically meaningful or had the biggest scientific impact from October 2018 through September 2019.